C
Chemo Mouthpiece
The Chemo Mouthpiece introduces a novel oral cryotherapy device for managing oral mucositis therapeutically
About Chemo Mouthpiece
Chemo Mouthpiece, LLC specializes in developing an innovative cryotherapy device designed to alleviate the symptoms of chemotherapy-related oral mucositis, a painful and debilitating condition affecting cancer patients. The device, known as 'The Chemo,' is composed of medical-grade silicone, fresh water, and a proprietary saline solution. It features a dual-chamber design where the inner chamber, filled with fresh water, freezes solid, while the outer chamber, filled with saline solution, remains extremely cold without freezing solid. This design ensures uniform cooling of the entire oral cavity, making it more effective and tolerable than traditional ice chips.
The company primarily serves cancer patients undergoing chemotherapy, providing a more efficient and comfortable solution to oral mucositis. Operating in the healthcare and medical device market, Chemo Mouthpiece, LLC follows a business-to-consumer (B2C) model, selling its product directly to patients and healthcare providers. Revenue is generated through direct sales of the device and potential licensing of its patented technology.
The Chemo Mouthpiece has been recognized by leading cancer care organizations such as NCCN, MASCC, and ONS for its effectiveness in reducing oral mucositis. The company has filed for numerous patents globally, with several already granted, ensuring a strong intellectual property position.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Wilmington, United States
- Employees
- 13
- Open positions
- 5
- Dealroom signal
- 45.4/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Oncology, Non-Invasive medical devices and treatments, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Sep 2024 | $5M | $76M | InfuSystem Holdings · Sanara MedTech | ↗ |
| EARLY VC✓Equity / VC | Feb 2024 | $10M | $40M | Redpoint eventures · TM3 Capital · Açolab Ventures · ArcelorMittal | ↗ |
Growth signals
Latest recorded traffic for Chemo Mouthpiece is 6.3K monthly website visits, down 34.4% over the last three months. Chemo Mouthpiece's team grew 8.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Redpoint eventures
TM3 Capital
Açolab Ventures
ArcelorMittal
InfuSystem Holdings
Sanara MedTech
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chemo Mouthpiece on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chemo Mouthpiece’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







